New data from Phase 3 studies demonstrated telaprevir-based combination therapy achieved higher viral cure rates (75%) compared to current therapies, with significant improvements in response to treatment across various patient groups. African Americans and those with advanced liver fibrosis or cirrhosis also showed improved SVR rates.
The discovery represents the first known structure of JNK3, a MAP Kinase family enzyme implicated in neurological diseases like epilepsy. Vertex's interdisciplinary approach may lead to new drugs against innovative targets, building on their track record of applying structural information to genomic discoveries.
A gene knockout mouse study by Vertex Pharmaceuticals and Yale researchers establishes the role of Caspase-9 in a specific biochemical pathway resulting in neuronal cell death. This finding suggests that blocking Caspase-9 may be a viable strategy for treating acute and chronic age-related neurological diseases.
Phase II data reveals amprenavir's potent drug profile, with sustained antiviral effects seen in patients treated with two-drug combinations. The medication is currently being evaluated in pivotal Phase III clinical trials and has an expected US new drug application filing later in 1998.
Researchers from Vertex Pharmaceuticals have solved the three-dimensional atomic structure of the hepatitis C virus NS3 helicase enzyme, an enzyme critical to viral replication. The achievement provides valuable insights into the mechanism of helicase enzymes and offers opportunities for accelerating antiviral drug development.
VA-10,367 has been shown to enhance the recovery of function following spinal cord injury through effects on neuronal regeneration. In a peripheral nerve injury model, the compound accelerated the days to onset of foot movement and walking, leading to recovery of function.